Европейски съюз -
български -
EMA (European Medicines Agency)
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Средства за дерматит, с изключение на кортикостероиди - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
България -
български -
БАБХ (Българска агенция по безопасност на храните)
enrofloxacin 10 % liquid 10 g/100 ml
ФАРМА ВЕТ ООД - Энрофлоксацин - перорален разтвор - 10 g/100 ml - бройлери
България -
български -
БАБХ (Българска агенция по безопасност на храните)
oxytetracyclin hydrochloride-ngp 7/ 0,340 g, 11/ 0,510 g, 22/ 1,020 g comprettae spumescentes песар
ngp pharm СВД ЕООД - Окситетрациклин хидрохлорид - песар - 0, 34 g/песар; 0, 51 g/песар; 1, 02 g/песар - кози, овце, свине
България -
български -
БАБХ (Българска агенция по безопасност на храните)
oxytetravit виж spc
ФАРМА ВЕТ ООД - виж ППК - прах за прилагане във вода за пиене - виж spc - прасета, птици
България -
български -
БАБХ (Българска агенция по безопасност на храните)
sicaden - s 3.00 g/100 ml емулсия
ВЕТПРОМ АД - dimethicone (Полидиметилсилоксан) - емулсия - 3.00 g/100 ml - говеда, кози, коне, овце
България -
български -
БАБХ (Българска агенция по безопасност на храните)
tetraneovit
ФАРМА ВЕТ ЕООД - Окситетрациклин hydrochloridum; неомицина сулфат, витамин А, Витамин Д3; витамин е; Витамин К, Витамин С, Витамин В1, Витамин В2, Витамин В6, Витамин В12; фолиева киселина, пантотенова киселина, никотинова киселина, биотин - прах за перорален разтвор - 6.00g/100g; 0.500g/100g; 50000 iu/100g; 5000 iu/100g; 7mg/100g; 10mg/100g; 250mg/100g; 6.5mg/100g; 25mg/100g; 10mg/100g; 0.025mg - агнета, прасета, птици, телета, ярета